Baird lowered the firm’s price target on Coherus Biosciences to $9 from $11 and keeps an Outperform rating on the shares. The firm said they are incrementally positive on paydown of debt and streamlining of revenue growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences Announces New Purchase Agreement Details
- Coherus BioSciences Sells CIMERLI® Franchise to Sandoz
- M & A News: Coherus (NASDAQ:CHRS) Surges after $170M Deal with Sandoz
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
- Coherus Biosciences presents positive Phase 2 data on casdozokitu